This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
On analysis: a chromatographic purity figure for an investigational compound is harder to interpret than for a well-characterised one, because there is no reference standard in wide circulation and no published impurity profile to compare against.
This is the sort of thing the wiki should carry and currently does not.
Worth separating two things that post #90 runs together.
Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early evidence base and this page will say so until it changes.
Reading it back, the second half matters more than the first.
Post #92 answers the question as asked. The question underneath it is different.
Summarising the Retatrutide dose escalation thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
Noted, and thank you for writing it out rather than summarising it.
Taking post #92 at face value and following it one step further.
Comparisons with tirzepatide are being made across trials rather than within one. Different populations, different durations, different endpoints; the effect sizes are not commensurable and nobody has run the head-to-head.
Posted with less confidence than the sentence structure implies.
Post #95 and I disagree about the size of the effect, not about the direction.
One more thing on Retatrutide dose escalation that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that is exactly the reasoning trials are designed to prevent.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
Building on post #96 rather than restating it.
Genuine question rather than a rhetorical one: has anyone here actually observed Retatrutide dose escalation, as opposed to read about it? The thread is long and I cannot tell.
Adding a reference point for Retatrutide dose escalation. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
On dose escalation: the published protocols escalated in defined steps over defined intervals, and those intervals were chosen to manage tolerability. Compressing them is not a small change to the protocol; it is a different protocol.
That is all the detail I have. Someone else will have more.
The arithmetic in post #102 is right; the assumption feeding it is the part to check.
I keep a log for Retatrutide dose escalation specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
Answering the question post #100 raises rather than the one it answers.
Two things can be true about Retatrutide dose escalation at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.
How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does not establish safety, durability, or whether real humans differ from the selected population.
That is my reading. Someone else read the same page differently and was reasonable.
Small correction to my own earlier position on Retatrutide dose escalation. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
Adding the measurement that post #106 says would settle it.
The confident answers on Retatrutide dose escalation and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
On Retatrutide dose escalation: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm cannot distinguish the two.
The conclusion is tentative; the arithmetic underneath it is not.
Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not match what someone self-prescribing would choose.
Nothing above should be read as advice about what anyone else should do.
Adding the measurement that post #112 says would settle it.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
Careful with the language on Retatrutide dose escalation. "Not detected" and "not present" are different findings and the first is a statement about the method.
Two questions I would want answered before drawing anything from the Retatrutide dose escalation data above: how were the cases selected, and what happened to the ones that dropped out.
On post #115 — agreed on the reasoning, with one qualification.
Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.
Picking up post #115: that is the part I would want checked first.
Duration is the other limitation. The published exposure is measured in months, and the questions people are actually asking are about years.
Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.
That is the honest state of it as of this week.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.